INCY vs MEDP: stock comparison and AI forecast
Incyte Corp (INCY) and Medpace Holdings, Inc. (MEDP) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
INCY Incyte Corp
- Price
- $119.65 +22.4% · 6M
- Market Cap
- $24.39B
- P/E Ratio
- 44.7x
- Size
- large-cap
- AI Forecast
MEDP Medpace Holdings, Inc.
- Price
- $653.11 +52.3% · 6M
- Market Cap
- $18.27B
- P/E Ratio
- 36.3x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- INCY is 1.3 times larger than MEDP by market capitalization ($24.39B against $18.27B).
- MEDP trades at 36.2 times trailing earnings, INCY at 44.6 times.
- Over the last six months MEDP returned +52.3% and INCY +22.4%.
- MEDP turns 18.2% of its revenue into net income, against 6.7% for INCY.
- MEDP carries 2.94 times debt per unit of equity, against 0.29 times for INCY.
- Both companies share the SEC industry classification Services-Commercial Physical & Biological Research.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | INCY | MEDP |
|---|---|---|
| Market Cap | $24.39B | $18.27B |
| P/E Ratio | 44.65x | 36.25x |
| P/B Ratio | 4.32x | 31.23x |
| EPS | $2.68 | $18.02 |
| Book Value/Share | $27.68 | $20.91 |
| Revenue/Share | $29.49 | $101.47 |
| FCF/Share | – | $23.87 |
Profitability & Margins
| Metric | INCY | MEDP |
|---|---|---|
| ROE | 7.2% | 88.5% |
| ROA | 5.5% | 22.5% |
| ROIC | 10.7% | 75.3% |
| Gross Margin | 92.7% | – |
| Operating Margin | 10.4% | 21.4% |
| Net Margin | 6.7% | 18.2% |
| EBT Margin | 13.2% | 22.1% |
| Tax Rate | 49.3% | 17.4% |
Financial Health
| Metric | INCY | MEDP |
|---|---|---|
| Current Ratio | 3.84x | 0.83x |
| Quick Ratio | 3.75x | – |
| D/E Ratio | 0.29x | 2.94x |
| Financial Leverage | 1.29x | 3.94x |
| Interest Coverage | 213.7x | 733.2x |
| Working Capital | $4.08B | -$251M |
Cash Flow
| Metric | INCY | MEDP |
|---|---|---|
| Operating Cash Flow | $745M | $723M |
| Free Cash Flow | – | $668M |
| Capital Spending | – | -$55M |
| OCF Growth YoY | -40.5% | 1.7% |
| FCF Growth YoY | – | -1.4% |
| FCF/Sales | – | 23.5% |
| CapEx/Sales | – | 1.9% |
Operational Efficiency
| Metric | INCY | MEDP |
|---|---|---|
| Asset Turnover | 0.82x | 1.23x |
| Receivables Turnover | 4.9x | 6.8x |
| Inventory Turnover | 3.3x | – |
| Fixed Assets Turnover | 8.6x | 16.2x |
| Days Sales Outstanding | 75 days | 54 days |
| Days Inventory | 112 days | – |
| Payables Period | 196 days | – |
| Cash Conversion Cycle | -9 days | – |
Income Statement
| Metric | INCY | MEDP |
|---|---|---|
| Total Revenue | $6.01B | $2.84B |
| Operating Income | $627M | $607M |
| Net Income | $403M | $518M |
| R&D Expense | $3.44B | – |
| SG&A Expense | $1.43B | $193M |
| Cost of Goods Sold | $439M | – |
Dividend & Shareholder Information
| Metric | INCY | MEDP |
|---|---|---|
| Shares Outstanding | 204M | 28M |
| Net Income Growth | -66.1% | 19.6% |
| EPS Growth | -53.8% | 26.0% |
INCY vs MEDP: stock comparison and AI forecast
Which is bigger, INCY or MEDP?
INCY is 1.3 times larger than MEDP by market capitalization ($24.39B against $18.27B).
Which is cheaper on earnings, INCY or MEDP?
MEDP trades at 36.2 times trailing earnings, INCY at 44.6 times.
Which stock performed better over the last six months, INCY or MEDP?
Over the last six months MEDP returned +52.3% and INCY +22.4%.
Which one does Intratio's AI model rank higher, INCY or MEDP?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.